Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017

  • ID: 4318764
  • Report
  • Region: Global
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Anavex Life Sciences Corp
  • TheraVida Inc
  • MORE
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report 'Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology and Genetic Disorders which include indications Alzheimer's Disease, Overactive Bladder, Depression, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Axillary Hyperhidrosis, Cognitive Disorders, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Rett Syndrome, Schizophrenia, Stroke and Urinary Incontinence.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Anavex Life Sciences Corp
  • TheraVida Inc
  • MORE
  1. Introduction
  2. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
  3. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
  13. Allergan Plc
  14. Anavex Life Sciences Corp
  15. FemmePharma Global Healthcare Inc
  16. Juniper Pharmaceuticals Inc
  17. Karuna Pharmaceuticals Inc
  18. TheraVida Inc
  19. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
  20. (ANAVEX-273 + donepezil hydrochloride) - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. (oxybutynin chloride + rivastigmine) - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. (trospium chloride + xanomeline tartrate) - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. ANAVEX-141 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. ANAVEX-273 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. oxybutynin chloride - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. oxybutynin chloride - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. oxybutynin chloride ER - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. THVD-201 - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
  61. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
  62. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
  63. Featured News & Press Releases
  64. May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
  65. May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
  66. Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
  67. Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in
  68. Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers
  69. Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients
  70. Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease
  71. Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
  72. Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model
  73. Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease
  74. Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
  75. Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC
  76. Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC
  77. Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC
  78. Jul 12, 2016: Anavex to Present at the Alzheimer’s Association International Conference (AAIC)
  79. Appendix
  80. Methodology
  81. Coverage
  82. Secondary Research
  83. Primary Research
  84. Expert Panel Validation
  85. Contact Us
  86. Disclaimer
List of Tables
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Number of Products by Stage and Mechanism of Actions, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Pipeline by Allergan Plc, H1
  11. Pipeline by Anavex Life Sciences Corp, H1
  12. Pipeline by FemmePharma Global Healthcare Inc, H1
  13. Pipeline by Juniper Pharmaceuticals Inc, H1
  14. Pipeline by Karuna Pharmaceuticals Inc, H1
  15. Pipeline by TheraVida Inc, H1
  16. Dormant Projects, H1
  17. Discontinued Products, H1
List of Figures
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Anavex Life Sciences Corp
  • FemmePharma Global Healthcare Inc
  • Juniper Pharmaceuticals Inc
  • Karuna Pharmaceuticals Inc
  • TheraVida Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll